Lisinopril exposure is inversely correlated with creatinine clearance in patients with chronic renal failure, highlighting the need for dose adjustment and potassium monitoring.
Answers are grounded in this paper and cite their sources.
Lisinopril exposure rises as creatinine clearance falls; case-report data leave open whether routine dose adjustment improves outcomes in chronic kidney disease.
Lisinopril, a new orally active angiotensin converting enzyme inhibitor, was given to eight patients with stable chronic renal failure, in a dose of 5 mg 24 h-1 for 1 week. Creatinine clearance of the subjects ranged from 0.22 to 1.11 ml s-1. Lisinopril pharmacokinetics were studied over 8 days. 2. There was a close correlation between creatinine clearance and total 'area under the curve' over the 8 days of study (r = -0.88, P less than 0.05), and plateau lisinopril concentration and creatinine clearance (r = -0.77, P less than 0.05). 3. Serum angiotensin converting enzyme activity was inhibited in proportion to log serum lisinopril concentration (r = -0.99, P less than 0.001). Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1. 4. Creatinine clearance was unaltered by treatment. Serum potassium rose to over 5 mmol 1-1 in four patients, without adverse clinical effect.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: